Abiraterone Acetate Tablets Product Specifications

Mechanism of Action

Abiraterone acetate is a CYP17A1 inhibitor, strategically blocking both 17 hydroxylase and 17,20lyase activities—thus inhibiting androgen synthesis in testes, adrenals, and prostate tumors. Ultimately, it reduces testosterone levels supporting prostate cancer growth

Research & Clinical Highlights

• Widely used in castrate-resistant prostate cancer (CRPC) internationally fr.wikipedia.org+6xian-janssen.com.cn+6pmc.ncbi.nlm.nih.gov+6.

• Clinical trials (e.g., STAMPEDE) showed significant overall survival benefit when added to standard hormone therapy en.wikipedia.org+1icr.ac.uk+1.

• Pharmacokinetics: high protein binding (~99.8%), half-life 12–24h, predominantly excreted in feces (~88%)

Research Applications

Ideal for use in:

• In vitro/in vivo prostate cancer models, especially CRPC

• Drug combination and pathway modulation studies

• Steroidogenesis and androgen-receptor signaling research

Handling & Storage

• Storage: Room temperature (20–25?°C), keep bottle tightly sealed

• Handling: Use standard lab PPE (gloves, goggles, lab coat)

• Packaging: Bottle containing blister packs; verify seals before use

References

1. Mechanism & pharmacology summary icr.ac.uk+15pmc.ncbi.nlm.nih.gov+15sciencedirect.com+15

2. Clinical efficacy and survival benefit data

3. Pharmacokinetic parameters & protein binding

4. China regulatory info & product details (NMPA H20193205)